

"Individual Commitment  
to a **Group Effort**... that is what  
makes a **Team Work**,  
a **Company Work**."

*- Vince Lombardi*

## FINANCIAL SUMMARY 10 Years' Performance

₹ In lakhs

### CAPITAL ACCOUNT

Particulars	2012-13	2013-14	2014-15	2015-16	2016-17	2017-18	2018-19	2019-20	2020-21	2021-22
Share Capital	418	418	418	1,253	1,253	1,253	1,253	1,253	2,505	2,505
Reserves	7,145	8,171	9,672	10,958	12,802	13,709	15,207	14,968	16,559	18,872
Borrowings	52	-	-	211	-	244	439	4,456	1,360	311
Gross Block	2,294	2,387	2,295	3,361	3,364	2,640	6,036	9,510	9,737	9,784
Net Block	1,308	1,233	982	1,850	1,759	2,262	5,502	8,404	7,142	6,152

### REVENUE ACCOUNT


Particulars	2012-13	2013-14	2014-15	2015-16	2016-17	2017-18	2018-19	2019-20	2020-21	2021-22
Total Revenue	24,490	27,055	28,874	32,973	22,454	24,863	32,537	31,117	44,250	49,184
Earnings Before Interest, Tax, Depreciation and Amortization	1,939	2,733	3,518	4,024	2,960	2,529	3,423	2,698	5,512	5,204
Profit before Tax	1,768	2,548	3,186	3,794	2,759	2,342	3,240	1,916	3,855	3,912
Profit After Tax	1,253	1,759	2,199	2,580	2,005	1,651	2,337	1,431	2,844	3,056
Earnings Per Share (₹)	15.01	21.06	26.00	10.3	8.00	6.59	9.33	5.71	5.67	6.10
Dividend Per Share (₹)	6.00	7.75	7.00	2.50	2.50	2.75	2.75	2.75	1.50	1.75

#### Notes :

- 1) EPS & DPS reported w.e.f. FY 2015-16 is after giving effect to Bonus Issue of Shares in the ratio of 2:1 i.e. 2 Bonus Shares for each Equity Share held.
- 2) EPS & DPS reported w.e.f. FY 2020-21 is after giving effect to Bonus Issue of Shares in the ratio of 1:1 i.e. 1 Bonus Shares for each Equity Share held.
- 3) Figures for the FY 2016-17 and onwards are reported as per Ind AS requirements.
- 4) The Board of Directors of the Company has recommended a final dividend of ₹ 1.75/- per equity share of face value of ₹ 5 /- each (35%), subject to shareholders' approval at the 62<sup>nd</sup> Annual General Meeting.


## Total Revenue

₹ in Lakhs




## EBITDA

₹ in Lakhs




## Reserves

₹ in Lakhs



## Outflow of Dividend

₹ in Lakhs



Note - Figures for the FY 2016-17 and onwards are reported as per Ind AS requirements.

# This includes Final dividend of F.Y. 2018-19 of ₹ 831 lakhs and Interim dividend of F.Y. 2019-20 of ₹ 831 lakhs.

\*The Board of Directors of the Company has recommended a final dividend of ₹ 1.75/- per equity share of face value of ₹ 5/- each (35%), subject to shareholders' approval at the 62<sup>nd</sup> Annual General Meeting.

## CONTENTS

Particulars	Page Nos.
Chairman's Message to the Shareholders	3
Vice Chairman's Message to the Shareholders	4
List of Board of Directors	5
List of Senior Management and Key Managerial Personnel	7
Corporate Information	8
Notice	9
Directors' Report	22
Management Discussion and Analysis	40
Corporate Governance Report	44
Certificate on Corporate Governance	63
Independent Auditor's Report	64
Balance Sheet as on March 31, 2022	74
Statement of Profit and Loss for the year ended on March 31, 2022	75
Cash Flow Statement	76
Notes to Financial Statements	79

## CHAIRMAN'S SPEECH

Dear Shareholders,

Our Operational Revenue for the financial year 2021-2022 amounted to Rs. 48,665 lakhs as against Rs. 43,196 lakhs for the previous year, an increase of 12.66 %

Our Profit Before Tax has gone up from Rs. 3,855 lakhs to Rs. 3,912 lakhs for this year.

For the year under review, the Company has recommended a Final Dividend of Rs. 1.75 per share i.e. @ 35% (Rs. 1.50/- per share i.e. @ 30% for the previous year) on Equity Shares of face value of Rs. 5/- each of the Company subject to the approval of the shareholders at the Annual General Meeting. The total dividend outgo shall be Rs. 876.96 lakhs as compared to same amount of Rs. 751.68 lakhs during the previous year.

We are happy to share that 11 new products are under development which are Aripiprazole, Fexofenadine Hcl, Vildagliptin, Sulfadiazine, Phenylephrine HCL, Sitagliptin, Sulfasalazine, Clotrimazole Theophylline, Caffeine, Doxofylline.

### Global Bulk Drug market:

Three segments - Branded Prescription drugs, Over-the-Counter (OTC) drugs and Generic Prescription drugs account for a majority of global bulk drug consumption.

The total global bulk drug consumption is expected to reach USD 215 billion by 2023 at a CAGR 6.5% during the forecast period out of which 80% is used for Branded Prescription drugs, 10% for OTC drugs and 10% for Generic Prescription drugs.

### Indian Bulk Drug market:

India is expected to be the 3<sup>rd</sup> largest global markets for Bulk Drugs with a 7.5% increase in market share. There are 1150 bulk drug units producing about 350 important Bulk Drugs. The market analyst forecast the API markets in India to grow at a CAGR of 11% over the period of 2021-2025.

### MAJOR EVENT SINCE THE CLOSE OF THE YEAR

I am glad to point out that the Company has successfully overcome lean patch with the end of the year on 31<sup>st</sup> March, 2022.

### Manufacturing

Anuh Pharma Ltd. is well positioned to service its existing and potential markets through its manufacturing operations at Tarapur in Maharashtra.

The Company enjoys cGMP approvals and all the facilities are built and operated according to cGMP (current Good Manufacturing Practices).

The Company is approved by European Directorate for the Quality of Medicines and HealthCare (EDQM) for the products Erythromycin Base, Erythromycin Ethyl Succinate, & Pyrazinamide. The Company has also got approval from WHO PQ Geneva authorities for Pyrazinamide and Sulfadoxine. The Company is also approved by (Comisión Federal para la Protección contra Riesgos Sanitarios) COFEPRIS, Mexico for Erythromycin Stearate, Erythromycin Estolate, Erythromycin Ethyl Succinate. The company has received The United States Food and Drug Administration (USFDA) and CEP for Ambroxol Hydrochloride during 2019-2020.

The Company has also received plant approvals from several MNCs.

### Research & Development

During the month of April 2012 the Company had acquired an existing Research & Development Laboratory in Mahape, Navi Mumbai from a Spanish Company. This Research & Development Laboratory has three sections, i.e. Analytical Development Lab, Chemical Synthesis Lab and a Pilot Plant. Each section is equipped with latest and sophisticated equipments and machineries.

This has helped us in intensifying our Research & Development activity with a view to enlarge our bulk drugs portfolio.

Before I conclude, I would like to record my gratitude to my colleagues on the Board, for their contribution and support during the year. I also wish to acknowledge the support given by the M/s. Sevantilal Kantilal & Co – our Guardian Company.

I would also like to thank all our Shareholders, Auditors and our Banker, HDFC Bank Ltd., for their patronage and support.

Thank you

**Jasvantlal G. Shah**  
Chairman

## Vice Chairman's Message to the Shareholders



**Mr. Bipin N. Shah**

**Vice Chairman**

Dear Shareholders,

It gives me great pleasure to address you all as we collectively continue to navigate through the challenges posed by the pandemic. I express our gratitude to all those with all your support.

Our Company has been bestowed with the responsibility of providing quality bulk drugs to formulation companies. Despite a challenging economy, during the financial year 2022, the Company recorded satisfactory performance by achieving Revenue and EBITDA

We have successfully performed throughout the year and provided timely service to all our esteemed clients.

As we reel under the effects of the COVID, we still continue to face similar challenges. With tremendous support from staff and workers, we are confident that we will keep the wheels of production rolling.

It is my great pleasure to present to you our Company's 62<sup>nd</sup> Annual Report in a nutshell.

Our Operational Revenue for the financial year 2021-2022 amounted to Rs. 48,665 lakhs as against Rs. 43,196 lakhs for the previous year, an increase of 12.66 %.

**Our Profit Before Tax has gone up from Rs. 3,855 lakhs to Rs. 3,912 lakhs for this year.**

**Our profit before tax as compared to last year has increased by 1.48 % from Rs. 3,855 lakhs to Rs. 3,912 lakhs and profit after tax has increased by 7.47 % from Rs. 2,844 lakhs to Rs. 3,056 lakhs.**

We could achieve above good results in spite of huge depreciation of Rs. 1,196 lakhs for the financial year 2021-2022.

### **EXPANSION PROJECT:**

Our "New Expansion project" is fully operational and due to this increased capacity, we hope to continuously achieve higher topline and bottom-line.

We continue to allocate total resources towards building the API and Bulk Drugs segment. Our R&D facility at Navi Mumbai works relentlessly on the development of newer and better pharmaceutical raw materials.

### **TRANSFORMATION:**

In order to generate long term sustainable value for shareholders, businesses need to continuously involve and transform themselves to build a strong foundation for future growth.

At Anuh Pharma, we have decided on a transformational journey to ensure that the Company is aligned in tune with the times.

With warm regards,

**Mr. Bipin N. Shah**

Vice Chairman  
Anuh Pharma Ltd.

## Board of Directors



**Mr. Jasvantlal G. Shah**  
Chairman



**Mr. Bipin N. Shah**  
Vice Chairman



**Mr. Lalitkumar P. Shah**  
Director



**Mr. Bharat N. Shah**  
Director



**Mr. Arun L. Todarwal**  
Director



**Dr. (Ms.) Mita C. Dixit**  
Director

## Board of Directors



**Mr. Harmanbhai T. Patel**  
Director



**Mr. Sandeep M. Joshi**  
Director



**Mr. Samir J. Shah**  
Director



**Mr. Ketan L. Shah**  
Director



**Mr. Ritesh B. Shah**  
Joint Managing Director



**Mr. Vivek B. Shah**  
Joint Managing Director

## Senior Management & Key Managerial Personnel



**Mr. Rajendrakumar C. Kotadia**  
Vice President - Marketing



**Dr. Rajiv P. Sutar**  
Vice President - Technical



**Mr. Darshan D. Rampariya**  
Chief Financial Officer



**Mr. Sanjay V. Barhate**  
Vice President - Quality



**Mr. Tejas S. Patel**  
General Manager - QA



**Mr. Gaurav S. Shah**  
Head Anti Malarials



**Mr. Surendra U. Rai**  
Assistant General Manager - QC



**Mr. Ketan N. Shah**  
Senior Marketing Executive



**Mr. Bharat Gangani**  
Company Secretary



**Mr. Kaushal H. Shroff**  
Senior Marketing Executive



**Mr. Nilesh S. Mohare**  
Assistant General Manager - QA



**Mr. Monil R. Shah**  
Marketing & Business  
Development Executive



**Mr. Bhavesh S. Mudaliar**  
Assistant General Manager  
- Production



**Mr. Babu K. Moghaveera**  
Assistant General Manager  
- Technical

## ANUH PHARMA LTD.

CIN: L24230MH1960PLC011586

### Sixty-Second Annual Report of the Board of Directors with the Audited Statement of Accounts for the year ended March 31, 2022

<b>Board of Directors</b>	: Mr. Jasvantlal Shah Mr. Bipin Shah Mr. Ritesh Shah Mr. Vivek Shah Mr. Lalitkumar Shah Mr. Bharat Shah Mr. Arun Todarwal Mr. Sandeep Joshi Mr. Harmanbhai Patel Dr. (Ms.) Mita Dixit Mr. Samir Shah Mr. Ketan Shah	Chairman - Independent Director Vice Chairman Joint Managing Director Joint Managing Director Director Director Independent Director Independent Director Independent Director Independent Director Director Director	(DIN: 00372600) (DIN: 00083244) (DIN: 02496729) (DIN: 02878724) (DIN: 00396345) (DIN: 00083354) (DIN: 00020916) (DIN: 00516409) (DIN: 07342390) (DIN: 08198165) (DIN: 00157396) (DIN: 00083326)
<b>Chief Financial Officer</b>	: Mr. Darshan Rampariya		
<b>Company Secretary &amp; Compliance Officer</b>	: Mr. Bharat Gangani		
<b>Auditors</b>	: M/s. Jayantilal Thakkar & Co. Chartered Accountants, (Firm Registration No. 104133W)		
<b>Bankers</b>	: HDFC Bank Ltd.		
<b>Registrars and Transfer Agents</b>	: Bigshare Services Private Limited Office No S6-2, 6 <sup>th</sup> Floor, Pinnacle Business Park, Next to Ahura Centre, Mahakali Caves Road, Andheri (East) Mumbai – 400093 Tel : +91-22-62638200; Fax: +91-22-62638299 Email: <a href="mailto:investor@bigshareonline.com">investor@bigshareonline.com</a> Web: <a href="http://www.bigshareonline.com">www.bigshareonline.com</a>		
<b>Registered Office</b>	: 3-A, Shivsagar Estate, North Wing, Dr. Annie Besant Road, Worli, Mumbai - 400018 Tel : +91-22-6622 7575 Fax: +91-22-6622 7600 Email: <a href="mailto:anuh@sk1932.com">anuh@sk1932.com</a> Web: <a href="http://www.anuhpharma.com">www.anuhpharma.com</a>		
<b>Factory</b>	: E-17/3, 17/4 & E-18 MIDC, Tarapur, Boisar, Dist. Palghar - 401506 Tel : +91-7410055574/75		
<b>R &amp; D Division</b>	: A-514, TTC Industrial Area, MIDC, Mahape, Navi Mumbai - 400701 Tel : +91-22-4119 3333 Fax: +91-22-4119 3300 Email: <a href="mailto:research@anuhpharma.com">research@anuhpharma.com</a> Web: <a href="http://www.aplrnd.com">www.aplrnd.com</a>		